Background {#Sec1}
==========

Myopia is a common condition exhibiting an "epidemic" during the past half-century. East and Southeast Asia appear to have a higher myopia prevalence, compared to Western and European populations, with Singapore, China, Hong Kong and Taiwan representing the regions where the problem is more common \[[@CR1]\]. Myopia is included in the 10 priority eye diseases in VISION 2020 campaign for the prevention of blindness and visual impairment, as declared by the World Health Organization \[[@CR2]\].

Myopia introduces significant social and psychological impact, as it appears to affect children's perception of their physical appearance, athletic competence and social acceptance \[[@CR3]\]. Myopia also imposes a considerable economic burden to societies. Annual expenses for myopia treatment are estimated to be greater than for other ocular diseases including age-related macular degeneration and primary open-angle glaucoma, as well as for non-ocular chronic pathologies, such as Parkinson's disease and chronic obstructive pulmonary disease \[[@CR4]\]. A treatment that would halt or at least decelerate myopia's progression rate is highly desirable, as severe myopia constitutes a substantial risk factor for several ocular conditions which can lead to blindness. These include retinal detachment, primary open angle glaucoma, cataract and macular degeneration \[[@CR1]\].

Several interventions have been attempted to control myopic progression, some of which showed no effect and others were effective but with limitations \[[@CR5]--[@CR8]\]. Long-term safety and efficacy of interventions to restrict myopia remains unresolved, resulting in the lack of universal consensus in myopia treatment \[[@CR9]--[@CR12]\]. As there appears to be no overview in existing literature, the aim of the present study is to synthesize evidence provided by systematic reviews (SRs) and meta-analyses (MAs) on myopia control.

Methods {#Sec2}
=======

Protocol and registration {#Sec3}
-------------------------

We used the term 'overview' for our synthesis of multiple intervention systematic reviews and meta-analyses, as proposed by the Cochrane Collaboration \[[@CR13]\] and reporting followed the PRIO-harms guidelines (Additional file [1](#MOESM1){ref-type="media"}: Appendix 1) \[[@CR14]\]. The protocol of this study is registered in the PROSPERO database (CRD42017068204) \[[@CR15]\] and published in *Systematic reviews* \[[@CR15]\]*.*

Ιnformation sources and search strategy {#Sec4}
---------------------------------------

Purposive literature search was conducted in the Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE) and Centre for Reviews and Dissemination (CRD) Health Technology Assessment (HTA) Database, using the keyword 'myopia'. A more comprehensive search strategy was applied in MEDLINE and EMBASE, using medical subject headings (MeSH) and text words related to spectacles, contact lenses, anti-muscarinic agents, myopia and children \[[@CR5], [@CR16]\] to find any recent primary studies not included in the published systematic reviews. The last search date was March 9, 2018. For all included studies, reference lists were also searched. MEDLINE search strategy is provided (Additional file [1](#MOESM1){ref-type="media"}: Appendix 2). No language, study type or date restrictions were used.

Eligibility criteria {#Sec5}
--------------------

### Participants {#Sec6}

Our overview target were children and adolescents, ≤ 18 years of age at baseline, diagnosed with myopia defined as spherical equivalent refraction ≤ − 0.25 dioptres, with or without astigmatism, without any ocular comorbidities including strabismus and amblyopia. Animals, adult population, patients not suffering from myopia, or patients with myopia and strabismus/amblyopia were excluded. Studies related to surgical interventions for myopia correction, e.g. refractive surgery were not considered.

### Interventions and comparators {#Sec7}

We included studies in which any optical or pharmacological intervention for myopia control was compared to single vision spectacles, contact lenses, or placebo. No restriction on duration and dose of treatment, if applicable, was imposed.

### Outcome measures {#Sec8}

Our primary outcomes regarded myopia progression and axial elongation as efficacy criteria. Myopia progression was assessed as mean change in refractive error, measured in dioptres. Mean change in axial length, measured in millimetres, was also evaluated. Outcomes reporting change in a 12-month or 24-month period were accepted and described. Reported adverse events (AE) were regarded as safety criteria.

### Study design {#Sec9}

Unit of analysis of this overview were SRs or meta-analyses of randomized controlled trials (RCTs), pseudo-RCTs, cohort and case-control studies. Network meta-analyses were also reviewed. Only human studies with full text available were analysed. Narrative reviews that do not systematically search the literature and do not critically appraise the quality of included studies were excluded.

Subsequently, primary studies included in eligible systematic reviews and meta-analyses were identified and employed as a unit of analysis to perform an extensive meta-analysis and provide effect estimates for myopia control interventions (thereafter referred to as index publications). The total of index publications included in the meta-analysis is provided in Additional file [1](#MOESM1){ref-type="media"}: Appendix 3. Levels of evidence as produced by the Oxford Centre for Evidence Based Medicine (OCEBM) were considered \[[@CR17]\]. Index publications of low level of evidence, i.e. poor quality cohort/case-control studies, case series, case reports or expert opinions were not included. Cohort and case-control studies were considered of low quality if they scored less than 5 points in Newcastle-Ottawa scale. Similarly, index publications without a control group or those comparing two or more different interventions were not included in the statistical analysis.

Study selection and data management {#Sec10}
-----------------------------------

Two independent authors (EP, AF) performed all screening steps. Title and abstract screening were conducted using the Mendeley citation management software. The overview authors screened the titles and abstracts against the eligibility criteria and obtained full reports for all titles that appeared to meet the inclusion criteria or where there was uncertainty. The same two independent authors (EP, AF) managed data in duplicate from each eligible study, using a data collection form in Microsoft Excel designed to include all the data required. Each SR or MA was initially evaluated to identify whether it matched the eligibility criteria of the overview. Subsequently, index publications contained in these SRs/MAs were individually reviewed. Data extraction was then performed for inclusion of eligible index publications in the meta-analysis. In cases where risk of bias of index publications was not available by the included SR or MA, two independent authors (EP, AF) completed the missing assessments. When an index publication was included in more than one SRs or MAs, outcome data were extracted from the most comprehensive study. A third author was involved to resolve any discrepancies, using the primary research paper (ABH).

Risk of bias assessment {#Sec11}
-----------------------

Two overview authors (EP, AF) independently assessed the methodological quality of each included SR and MA using the Risk Of Bias In Systematic Reviews (ROBIS) tool \[[@CR18]\]. The quality of evidence was evaluated by two independent authors (EP, AF) using four domains of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool: study limitations, imprecision, inconsistency of results, and indirectness and a summary of findings for each outcome of interest was designed using GRADEpro software \[[@CR19], [@CR20]\]. In order to minimize the subjectivity of quality assessment process, a third reviewer was involved to resolve any discrepancies (ABH).

The list of included index publications in eligible SRs/MAs was reviewed in order to identify those contained in two or more reviews. We generated a citation matrix presenting all the SRs/MAs in columns and all included index publications in rows. We estimated the overlap by calculating the corrected covered area (CCA), to assess if specific index publications are overrepresented. The formula for calculating CCA is: **CCA =** $\documentclass[12pt]{minimal}
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                \begin{document}$$ \frac{\mathrm{N}-\mathrm{r}}{\mathrm{rc}-\mathrm{r}} $$\end{document}$ where N = sum of the included studies, r = rows (number of unique studies), c = columns (number of reviews). CCA reflected the degree of actual overlap, as it is not influenced by large reviews. Should high or very high overlap be detected, which is interpreted as CCA equal to or more than 10%, we planned to retain the review which is (1) the most recent, (2) containing a higher amount of information, and (3) the most rigorous in terms of methodology, as assessed by ROBIS tool and GRADE scale \[[@CR21], [@CR22]\]. In addition, two independent overview authors (EP, AF) examined possible presence of meta-biases, including publication bias, selective outcome reporting and dual co-authorship. Handling of inconsistency for meta-analyses and other potential sources of bias are also reported (Additional file [1](#MOESM1){ref-type="media"}: Table S1) \[[@CR23]--[@CR26]\].

Data synthesis and analysis {#Sec12}
---------------------------

Index publications included in eligible systematic reviews and meta-analyses were employed as a unit of analysis to perform a meta-analysis using Review Manager software version 5.3. Continuous outcomes were expressed using mean differences with 95% confidence intervals (CIs) and dichotomous outcomes were expressed using odd ratios (ORs) with 95% CIs. Data were synthesized using random-effects models due to the inconsistency across the RCTs and cohort studies. Subgroup analyses according to study design (RCTs and observational studies) were performed and whenever no subgroup differences were obtained the overall effect was reported. We pooled the results referring to one eye only, to each eye separately, or to the average of both eyes, depending on the data analysed by each index publication design (Additional file [1](#MOESM1){ref-type="media"}: Table S2). Sensitivity analyses excluding studies of lower methodological quality, when each eye was reported separately or those introducing substantial inconsistency were also conducted.

Results {#Sec13}
=======

Literature search yielded 3057 records, 2319 non-duplicates were screened and 27 retrieved in full text (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR14]\]. Nine studies were subsequently excluded (Additional file [1](#MOESM1){ref-type="media"}: Table S3), leaving 18 SRs and meta-analyses to be included in this overview \[[@CR5], [@CR6], [@CR9]--[@CR12], [@CR27]--[@CR38]\]**.**Fig. 1Flow chart for Overview of Systematic Reviews (OoSRs). \*Index publication is the first occurrence of a primary publication in the included reviews. \*\*Additional eligible primary studies that had not been initially identified by the search of the relevant reviews or obtained by updating the search of the included reviews

Table [1](#Tab1){ref-type="table"} summarizes the main characteristics of the 18 eligible SRs/MAs. These were published between 2002 and 2017. Five studies are SRs and meta-analyses, four performed systematic review of literature with qualitative syntheses of findings, eight performed meta-analyses, and one is a network meta-analysis. Four studies investigated atropine, four analysed orthokeratology, two focused on outdoors exposure, one examined the efficacy of acupuncture, and two investigated the use of multifocal lenses. The remaining five studies examined multiple interventions for myopia control.Table 1Characteristics of included studiesReview &Type of StudyDatabases searched and last assessedNo. of primary studies (sample size)EthnicityAge range (average age) in yearsTreatmentControlOverview outcomesWalline et al. 2011 \[[@CR5]\]\
SR & meta-analysisCENTRAL, MEDLINE, EMBASE, LILACS, *m*RCT, ClinicalTrials.gov (10/2011)23 (4696)Israel, Malaysia, China, USA, Finland, Hong Kong, Japan, Taiwan, Denmark6--18Undercorrection, multifocal spectacles, bifocal soft contact lenses, novel lenses, RGPCLs, anti-muscarinic medicationsFull correction spectacles, SVLs, single vision contact lenses, placeboChange in RE, change in ALSherwin et al. 2012 \[[@CR36]\]\
SR & meta-analysisMEDLINE, EMBASE, Web of Science, CENTRAL (NA)23 (80--3009)Singapore, Australia, Jordan, China, USA0.5--20Outdoor exposureNARisk for myopia progressionWen et al. 2015 \[[@CR33]\]\
SR & meta-analysisMEDLINE, EMBASE, Cochrane Library, WHO international Clinical Trials Registry Platform, ClinicalTrials.gov (11/2014)8 (769)Chinese, Caucasian, Japanese6--15OKSingle vision spectacles, contact lensesChange in ALXiong et al. 2017 \[[@CR12]\]\
SR & meta-analysisPubMed, EMBASE, Cochrane Library (12/2015)25 (50--5048)China, Taiwan, Singapore, Australia, UK, USA, Turkey6--18^a^Outdoor exposureNARisk of myopia progressionGong et al. 2017 \[[@CR9]\]\
SR & meta-analysisPubMed, EMBASE, Cochrane Central Register of Controlled Trials (04/2016)19 (3137)Taiwan, USA, Singapore, China, Hong Kong5--17AtropineAtropine, control conditionsMyopia progression, adverse eventsSaw et al. 2002 \[[@CR6]\]\
SRMEDLINE, EMBASE, Cochrane Library, Science Citation Index (2000)26 (32--247)Taiwan, USA, Finland, DenmarkNAAtropine, timolol, bifocals, multifocal lenses, multifocal lenses + atropine, contact lensesTropicamide, cyclopentolate, lenses, bifocals, single vision spectaclesChange in REWei et al. 2011 \[[@CR27]\]\
SRCENTRAL, MEDLINE, EMBASE, AMED, LILACS, *m*RCT, ClinicalTrials.gov, NCCAM, CBM, CNKI, VIP (07/2011)2 (131)Taiwan\<  18Auricular stimulation with 0.25% atropine, acupressure and interactive multimediaPlacebo, sham acupuncture, atropine eyedrops 0.25% or 0.5%, non-specific treatment, e.g. vitamin E, spectaclesChange in RE, change in ALChassine et al. 2015 \[[@CR38]\]\
SRMEDLINE, Google Scholar (12/2014)19 (26--1209)Αustralia, Singapore, China, USA,\
Malaysia, Canada,\
New Zealand,\
RussiaNAOutdoor activity, atropine, undercorrection, bifocal (prismatic) spectacles, CLs,\
multifocal SCLs, OK, RGPCLsFull correction,\
SVLs, atropine,\
PALs, SCLsMyopia progressionShih et al. 2016 \[[@CR28]\]\
SRUS FDA website, PubMed, ClinicalTrials.gov, Cochrane Library (04/2015)5 (96--400)Taiwan,\
Singapore6--13Atropine 0.1--1%Saline,\
cyclopentolate,\
atropine,\
tropicamide,\
atropine + multifocal spectacles,\
multifocal spectacles, SVLsChange in RE, adverse eventsSong et al. 2011 \[[@CR29]\]\
Meta-analysisCochrane Library, PubMed, US FDA website, ClinicalTrials.gov, European regulatory authorities, manufacturer's product information sheets, CBMDISC (2009)6 (823)Taiwan, Hong Kong, Singapore5--15Atropine 0.1--1%Atropine,\
atropine + multifocal spectacles, multifocal spectacles/SVLs,\
auricular acupoints,\
tropicamide,\
cyclopentolateChange in RE, change in ALLi et al. 2011 \[[@CR30]\]\
Meta-analysisMEDLINE, EMBASE, Cochrane Library, Science Citation Index, Chinese Clinical Trial Registry, WHO international Clinical Trials Registry Platform, ClinicalTrials.gov (10/2010)9 (1464)USA, Hong Kong, China, Taiwan, Japan, Canada, Finland6--13Multifocal lenses (bifocal lenses, PALs)SVLsChange in RE, change in ALLi et al. 2014 \[[@CR37]\]\
Meta-analysisMEDLINE, EMBASE, Cochrane Library, WHO international Clinical Trials Registry Platform, ClinicalTrials.gov (04/2013)11 (1815)Taiwan, Hong Kong, Singapore, United States8--15Atropine 0.025--1%Placebo,\
Tropicamide, blankChange in RESun et al. 2015 \[[@CR31]\]\
Meta-analysisMEDLINE, EMBASE (01/2014)7 (435)Hong Kong, Japan, Spain,\
USA6--16OKSpectacles,\
SCLsChange in ALSi et al. 2015 \[[@CR32]\]\
Meta-analysisPubMed, EMBASE, Cochrane Library (11/2013)7 (435)Hong Kong, Japan, Spain,\
USA6--16OKSVLs, spectacles, SCLsChange in ALLi et al. 2016 \[[@CR10]\]\
Meta-analysisMEDLINE, EMBASE, Cochrane Library, Chinese Clinical Trial Registry, WHO international Clinical Trials Registry Platform, ClinicalTrials.gov (01/2015)9 (667)Hong Kong, Japan, China,\
Spain6--16OKSVLsChange in AL, adverse eventsLi et al. 2017 \[[@CR11]\]\
Meta-analysisMEDLINE, EMBASE, Cochrane Library, Chinese Clinical Trial Registry, WHO international Clinical Trials Registry Platform, ClinicalTrials.gov (05/2016)8 (587)USA, China,\
Hong Kong,\
New Zealand, Japan, Spain6--18SCLs with concentric ring bifocal and peripheral add multifocal designssingle vision SCLs or spectaclesChange in RE, change in ALCui et al. 2017 \[[@CR35]\]\
Meta-analysisMEDLINE, Cochrane, EMBASE, Google Scholar (09/2015)5 (673)USA, Singapore, East Asia6--16RGPCLsSCLs, spectacles, OKChange in RE, change in ALHuang et al. 2016 \[[@CR34]\]\
Network meta-analysisMEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, WHO international Clinical Trials Registry Platform, ClinicalTrials.gov (08/2014)30 (5387)Israel, Malaysia, Hong Kong, USA, Denmark,\
Finland, Japan,\
China, New England,\
Singapore, Taiwan\< 18Atropine, pirenzepine,\
timolol, cyclopentolate, SVLs,\
OK, RGPCLs, bifocal spectacles\
outdoor activity, PALs,\
prismatic bifocals, peripheral defocus modifying spectacles and lenses, SCLsTropicamide, SVLsChange in RE, change in AL*AL* axial length, *AMED* Allied and Complementary Medicine Database, *CBM* Chinese Biological Medicine Database, *CBMDISC* Chinese Biomedical Literature Analysis and Retrieval System for Compact Disc, *CLs* contact lenses, *CNKI* China National Knowledge Infrastructure, *FDA* Food and Drug Administration, *LILACS* Latin American and Caribbean Health Sciences Literature Database, *mRCT meta*Register of Controlled Trials, *NA* not available, *NCCAM* National Center for Complementary and Alternative Medicine, *No.* number, *OK* orthokeratology, *RE* refractive error, *RCTs* randomized controlled trials, *RGPCLs* rigid gas permeable contact lenses, *PALs* progressive addition lenses, *SCLs* soft contact lenses, *SVLs* single vision lenses, *SVSCLs* single vision soft contact lenses, *SR* systematic review, *WHO* World Health Organization^a^Age range refers to the majority of participants

Overlapping {#Sec14}
-----------

The 18 included SRs and MAs comprised 226 overlapping index publications, of which 110 were unique. Two recently published RCTs not included in the 18 SRs/MAs were also identified through literature search and added to the index publications. A citation matrix presenting all the included SRs/MAs in columns and index publications in rows is provided in Additional file [1](#MOESM1){ref-type="media"}: Table S4. Index publications represented in more than one eligible reviews are recognized in the citation matrix. In order to avoid potential double counting of outcomes, we calculated the degree of actual overlap by estimating the CCA:$$\documentclass[12pt]{minimal}
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As CCA is estimated at 6.2%, the overlap is in the moderate range reflecting a moderate risk of skewed reporting \[[@CR21], [@CR22]\]. Out of the 112 index publications, 44 matched our eligibility criteria and were included in the meta-analysis. These consisted of 28 RCTs and 16 observational studies, and reported data on a total of 6400 patients.

Assessment of methodological quality {#Sec15}
------------------------------------

Qualitative, domain-based rating of methodological quality of eligible studies with ROBIS tool is provided in Additional file [1](#MOESM1){ref-type="media"}: Table S5 \[[@CR18]\]. The overall risk of bias was 'low' in 14 reviews \[[@CR5], [@CR6], [@CR9]--[@CR11], [@CR27]--[@CR35]\]**,** 'unclear' in three \[[@CR12], [@CR36], [@CR37]\] and 'high' in one review \[[@CR38]\].

With regard to 'Study eligibility criteria' domain, two studies \[[@CR6], [@CR38]\] were judged with 'high concern' due to imprecisely defined eligibility criteria, publication status and/or language limitations. One study \[[@CR38]\] was judged with 'high' and one \[[@CR29]\] with 'unclear concern' in 'Identification and selection of studies' domain because of limited details regarding search strategy and unclear study selection process. Domain 3 assessed the methodology used for data collection and study appraisal, in which two studies \[[@CR6], [@CR28]\] were judged with 'unclear' and one \[[@CR38]\] with 'high concern', due to lack of information on included studies' characteristics for appropriate interpretation of findings, or because of inappropriate or no risk of bias assessment of index publications. Fifteen eligible reviews reported quality assessment of the included index publications. Four \[[@CR29]--[@CR32]\] used the Jadad scale and four \[[@CR10], [@CR11], [@CR33], [@CR37]\] combined Jadad with Newcastle Ottawa scale for observational studies, four \[[@CR5], [@CR27], [@CR34], [@CR35]\] used the Cochrane Collaboration Risk of Bias tool, one \[[@CR9]\] combined the Cochrane tool with Newcastle Ottawa scale and two \[[@CR12], [@CR36]\] used other tools. Three reviews \[[@CR6], [@CR28], [@CR38]\] did not report formal assessment of included index publications. In 'Synthesis and findings' domain, three studies \[[@CR36]--[@CR38]\] were judged with 'high' and one \[[@CR12]\] with 'unclear concern', due to inappropriate quantitative or qualitative synthesis.

None of the eligible studies reported a GRADE assessment. Two authors (EP, AF) independently rated the quality of evidence for our outcomes using the GRADE scale (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}), \[[@CR19]--[@CR21]\]. Quality was assessed as 'high' in one outcome, 'moderate' in 41, 'low' in 12 and 'very low' in 23 outcomes examining efficacy or safety (Additional file [1](#MOESM1){ref-type="media"}: Appendix 6). Low/very low quality is due to a number of index publications being at risk of bias from elements involving imprecision, inconsistency and limitations including lack of blinding or allocation concealment and loss to follow-up.Table 2Primary outcomes from baseline (1 year) - Change in refractive errorOutcomeComparisonNumber of subjects (primary studies)Measure of effect (95% CI)Direction of effectI^2^ (%)Change in refractive errorUndercorrected versus fully corrected spectacles142 (2)MD = 0.15 (0.00 to 0.29)Favours fully corrected spectacles0Bifocal spectacles versus SVLs259 (2)MD = − 0.09 (− 0.19 to 0.02)Favours bifocal spectacles01% atropine versus placebo - RCTs604 (3)MD = − 0.78 (− 1.30 to − 0.25)Favours atropine971% atropine versus control - cohort studies798 (3)MD = − 0.39 (− 0.59 to − 0.19)Favours atropine260.025 and 0.05% atropine versus control224 (3)MD = − 0.51 (− 0.60 to − 0.41)Favours atropine90.01% atropine versus control60 (1)MD = − 0.50 (− 0.76 to − 0.24)Favours atropineN/A2% pirenzepine gel versus placebo84 (1)MD = − 0.30 (− 0.51 to − 0.09)Favours pirenzepineN/ARGPCLs versus spectacles or SCLs420 (2)MD = − 0.08 (− 0.19 to 0.02)Favours RGPCLs91Concentric ring bifocal SCLs versus SVSCLs264 (3)MD = − 0.31 (− 0.60 to 0.02)Favours concentric ring bifocal SCLs88Peripheral add multifocal SCLs versus SVLs - RCTs294 (5)MD = − 0.23 (− 0.31 to − 0.14)Favours peripheral add multifocal SCLs0ΟΚ versus SCLs or SVLs39 (1)MD = − 0.27 (− 0.50 to − 0.04)Favours OKN/APALs versus SVLs206 (2)MD = − 0.10 (− 0.21 to 0.00)Favours PALs0*CI* confidence interval, *MD* Mean Difference, *N/A* not applicable, *PALs* progressive addition lenses, *RCTs* randomized controlled trials, *RGPCLs* rigid gas permeable contact lenses, *SCLs* soft contact lenses, *SVLs* single vision lenses, *SVSCLs* single vision soft contact lensesTable 3Primary outcomes from baseline (1 year) -- Change in axial lengthOutcomeComparisonNumber of subjects (primary studies)Measure of effect (95% CI)Direction of effectI^2^ (%)Change in axial lengthUndercorrected versus fully corrected spectacles94 (1)MD = 0.05 (− 0.01 to 0.11)Favours full correctionN/ARGPCLs versus spectacles or SCLs415 (2)MD = − 0.02 (− 0.05 to 0.10)Favours spectacles/SCLs02% pirenzepine gel versus placebo264 (2)MD = − 0.10 (− 0.18 to − 0.01)Favours pirenzepine0Concentric ring bifocal SCLs versus SVSCLs264 (3)MD = − 0.12 (− 0.19 to − 0.06)Favours concentric ring bifocal SCLs661% atropine versus control586 (3)MD = − 0.36 (− 0.41 to − 0.30)Favours atropine46Peripheral add multifocal SCLs versus SVLs - RCTs294 (5)MD = − 0.10 (− 0.14 to − 0.05)Favours peripheral add multifocal SCLs37ΟΚ versus SCLs or SVLs524 (8)MD = − 0.19 (− 0.21 to − 0.16)Favours OK0PALs versus SVLs211 (2)MD = − 0.08 (− 0.14 to 0.02)Favours PALs65*CI* confidence interval, *MD* Mean Difference, *N/A* not applicable, *OK* Orthokeratology, *PALs* progressive addition lenses, *RGPCLs* rigid gas permeable contact lenses, *SCLs* soft contact lenses, *SVLs* single vision lenses, *SVSCLs* single vision soft contact lensesTable 4Primary outcomes from baseline (2 years) -- Change in refractive errorOutcomeComparisonNumber of subjects (primary studies)Measure of effect (95% CI)Direction of effectI^2^ (%)Change in refractive errorUndercorrected versus fully corrected spectacles142 (2)MD = 0.17 (0.12 to 0.23)Favours fully corrected spectacles0Bifocal spectacles versus single vision lens spectacles351 (3)MD = − 0.19 (− 0.59 to 0.21)Favours bifocal spectacles851% atropine versus placebo400 (1)MD = − 0.92 (− 1.08 to − 0.76)Favours atropineN/A2% pirenzepine gel versus placebo74 (1)MD = − 0.41 (− 0.70 to − 0.12)Favours pirenzepineN/ARGPCLs versus spectacles or SCLs398 (2)MD = − 0.16 (− 0.33 to − 0.00)Favours RGPCLs92Concentric ring bifocal SCLs versus SVSCLs128 (1)MD = − 0.20 (− 0.38 to − 0.02)Favours concentric ring bifocal SCLsN/APeripheral add multifocal SCLs versus SVLs99 (2)MD = − 0.50 (− 0.65 to − 0.35)Favours peripheral add multifocal SCLs0ΟΚ versus SCLs or SVLs39 (1)MD = − 0.66 (−1.01 to − 0.31)Favours OKN/APALs versus SVLs940 (4)MD = − 0.15 (− 0.40 to 0.11)Favours PALs89*CI* confidence interval, *MD* Mean Difference, *N/A* not applicable, *PALs* progressive addition lenses, *RGPCLs* rigid gas permeable contact lenses, *SCLs* soft contact lenses, *SVLs* single vision lenses, *SVSCLs* single vision soft contact lensesTable 5Primary outcomes from baseline (2 years) -- Change in axial lengthOutcomeComparisonNumber of subjects (primary studies)Measure of effect (95% CI)Direction of effectI^2^ (%)Change in axial lengthUndercorrected versus fully corrected spectacles94 (1)MD = 0.06 (− 0.04 to 0.16)Favours full correctionN/ABifocal spectacles versus single vision lens spectacles89 (1)MD = − 0.20 (− 0.31 to − 0.09)Favours bifocal spectaclesN/A1% atropine versus placebo400 (1)MD = − 0.36 (− 0.43 to − 0.29)Favours atropineN/A2% pirenzepine gel versus placebo74 (1)MD = − 0.12 (− 0.29 to 0.05)Favours pirenzepineN/ARGPCLs versus spectacles or SCLs394 (2)MD = 0.03 (− 0.05 to 0.12)Favours spectacles or SCLs0Concentric ring bifocal SCLs versus SVSCLs128 (1)MD = − 0.12 (− 0.20 to − 0.04)Favours concentric ring bifocal SCLsN/APeripheral add multifocal SCLs versus SVLs99 (2)MD = − 0.13 (− 0.20 to − 0.06)Favours peripheral add multifocal SCLs0ΟΚ versus SCLs or SVLs663 (11)MD = − 0.27 (− 0.31 to − 0.23)Favours OK0PALs versus SVLs791 (3)MD = −0.10 (− 0.20 to 0.00)Favours PALs78*CI* confidence interval, *N/A* not applicable, *OK* Orthokeratology, *PALs* progressive addition lenses, *RGPCLs* rigid gas permeable contact lenses, *SCLs* soft contact lenses, *SVLs* single vision lenses, *SVSCLs* single vision soft contact lensesTable 6Primary outcomes from baseline -- Adverse EventsOutcomeComparisonNumber of subjects (primary studies)Measure of effect (95% CI)Direction of effectI^2^ (%)Allergic or hypersensitivity reactions or discomfort1% atropine versus control446 (2)OR = 8.91 (1.04, 76.03)Favours control0Blurred near vision1% atropine versus control540 (2)OR = 9.47 (1.17, 76.78)Favours control0Contact lens-related discomfort/Unwillingness to wear contact lensesConcentric ring bifocal SCLs versus SVSCLs261 (2)OR = 0.95 (0.49, 1.81)Favours concentric ring bifocal SCLs0Mild corneal erosionΟΚ versus SCLs or SVLs151 (2)0R = 4.56 (0.49, 42.25)Favours SCLs/SVLs0Papillae/Follicles2% pirenzepine gel versus control323 (3)OR = 3.21 (0.95, 10.88)Favours control74Medication residue on eyelids or eye2% pirenzepine gel versus control323 (3)OR = 0.77 (0.38, 1.59)Favours pirenzepine33Abnormality of accommodation2% pirenzepine gel versus control323 (3)OR = 16.92 (6.27, 45.64)Favours control0Itching, eye2% pirenzepine gel versus control323 (3)OR = 1.01 (0.54, 1.90)No difference0Visual acuity decreased (subjectively)2% pirenzepine gel versus control323 (3)OR = 3.89 (0.93, 16.27)Favours control33Injection2% pirenzepine gel versus control323 (3)OR = 0.92 (0.22, 3.73)Favours pirenzepine74Fluorescein staining2% pirenzepine gel versus control323 (3)OR = 0.57 (0.23, 1.44)Favours pirenzepine45Burn/Sting, eye, on instillation2% pirenzepine gel versus control323 (3)OR = 1.84 (0.76, 4.46)Favours control0Eye/Vision, blurred2% pirenzepine gel versus control323 (3)OR = 1.17 (0.52, 2.63)Favours control0Erythema, eyelids2% pirenzepine gel versus control110 (2)OR = 0.69 (0.01, 41.23)Favours pirenzepine76Eyelid abnormality2% pirenzepine gel versus control110 (2)OR = 1.73 (0.27, 11.12)Favours control0Photophobia2% pirenzepine gel versus control110 (2)OR = 1.57 (0.35, 6.96)Favours control0Eye pain2% pirenzepine gel versus control110 (2)OR = 2.07 (0.33, 12.98)Favours control0Cough, increased2% pirenzepine gel versus control323 (3)OR = 1.06 (0.59, 1.92)No difference0Infection, respiratory2% pirenzepine gel versus control297 (2)OR = 1.32 (0.69, 2.51)Favours control0Rhinitis/Sinusitis2% pirenzepine gel versus control323 (3)OR = 1.08 (0.42, 2.76)No difference28Fever2% pirenzepine gel versus control297 (2)OR = 1.07 (0.51, 2.24)No difference0Abdominal pain2% pirenzepine gel versus control323 (3)OR = 2.42 (0.88, 6.62)Favours control0Headache2% pirenzepine gel versus control323 (3)OR = 1.30 (0.66, 2.56)Favours control0Flu syndrome2% pirenzepine gel versus control297 (2)OR = 0.54 (0.26, 1.13)Favours pirenzepine0Pharyngitis2% pirenzepine gel versus control323 (3)OR = 1.07 (0.48, 2.37)No difference0Rash/Allergic reaction2% pirenzepine gel versus control323 (3)OR = 1.77 (0.51, 6.12)Favours control22Cold, common2% pirenzepine gel versus control110 (2)OR = 0.60 (0.25, 1.42)Favours pirenzepine0Accidental injury2% pirenzepine gel versus control110 (2)OR = 2.32 (0.74, 7.22)Favours control0*CI* confidence interval, *OK* Orthokeratology, *OR* odds ratio, *RR* risk ratio, *SCLs* soft contact lenses, *SVLs* single vision lenses, *SVSCLs* single vision soft contact lense

Quality of the 44 index publications included in the meta-analysis was adequate. More than 50% of the RCTs were at low risk of bias for random sequence generation and allocation concealment and more than 80% of RCTs were at low risk of bias for selective outcome reporting. Nonetheless, only 20% of RCTs achieved appropriate blinding of participants and outcome assessors, while almost 70% were at high risk for incomplete outcome data. Three RCTs were assessed with Jadad scale and scored 4 or above, while one scored 2. More than 90% of included cohort studies were awarded with 8 or more stars in Newcastle-Ottawa Quality Assessment scale. Risk of bias assessments of index publications as presented in the eligible SRs/MAs are shown in Additional file [1](#MOESM1){ref-type="media"}: Tables S6, S7 and S8.

Synthesis of results {#Sec16}
--------------------

The included SRs and MAs provided outcome data relating to the following comparisons: Undercorrected vs fully-corrected spectacles, bifocal spectacles vs single vision lens spectacles (SVLs), atropine vs placebo, pirenzepine gel vs placebo, rigid gas permeable contact lenses (RGPCLs) vs spectacles or soft contact lenses (SCLs), concentric ring bifocal SCLs vs single vision soft contact lenses (SVSCLs), peripheral add multifocal SCLs vs SCLs or SVLs, OK vs SCLs or SVLs, progressive addition lenses (PALs) vs SVLs. The outcomes assessed included change in refractive error and change in axial length from baseline to 1 year and from baseline to 2 years. These outcomes were identified a priori as being of interest for this overview \[[@CR15]\]. Safety of myopia interventions was assessed by quantitative analysis of the number and type of reported adverse events.

Effects of interventions {#Sec17}
------------------------

### Undercorrected vs fully-corrected spectacles {#Sec18}

Two RCTS encompassing 142 children investigated the effect of undercorrection in myopic progression. The overall pooled analysis revealed that the undercorrected group showed greater change in refractive error (RE) in 1 year (MD 0.15, 95% CI 0.00 to 0.29), and in 2 years from baseline (MD 0.20, 95% CI 0.01 to 0.39) and the evidence quality of this outcome was considered moderate (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendices 4 and 6).

### Bifocal spectacles vs single vision lens spectacles {#Sec19}

Two RCTs (259 children) examined the effect of bifocal spectacles in myopia control and showed no change in RE in 1 year from baseline (MD -0.09, 95% CI -0.19 to 0.02; GRADE evidence: moderate; Table [2](#Tab2){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendices 4 and 6). Three RCTs (351 children) reported no change in RE using bifocal spectacles in 2 years from baseline (MD -0.19, 95% CI -0.59 to 0.21; GRADE evidence: low; Table [3](#Tab3){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendices 4 and 6). These 3 trials appeared to be inconsistent (*I*^*2*^ = 85%). Sensitivity analysis excluding *Parsinnen* et al. demonstrated no difference in the effect of bifocal spectacles.

### 1% atropine vs placebo {#Sec20}

Three RCTs (604 children) and three cohort studies (798 children) provided outcomes on the effect of 1% atropine eyedrops in refraction change in 1 year, (Table [2](#Tab2){ref-type="table"}). Subgroup analysis of the three trials reported a change of − 0.78D, favouring atropine (95% CI, − 1.30 to − 0.25) with moderate quality of evidence (Additional file [1](#MOESM1){ref-type="media"}: Appendix 6). Due to high inconsistency (*I*^*2*^ = 97%), sensitivity analysis excluding *Yi* et al. revealed a change of − 0.54D, also favouring atropine (95% CI, − 0.76 to − 0.33), with moderate inconsistency among the two studies (*I*^*2*^ = 54%). Treatment effect reported by cohort studies showed an increase in refraction for the subgroup receiving placebo. Mean change in RE over 1 year was − 0.39D, favouring the use of atropine (95% CI, − 0.59 to − 0.19).

Two RCTs (540 children) and one cohort study (46 children) compared mean axial length (AL) change between 1% atropine eyedrops and placebo in 1 year (Table [4](#Tab4){ref-type="table"}). Two trials revealed that atropine administration decreased AL change by − 0.35 mm (95% CI, − 0.38 to − 0.31). Treatment effect provided by the cohort study also favoured atropine, which showed AL change of − 0.61 mm (95% CI, − 0.88 to − 0.34). The overall treatment effect (586 children) showed that 1% atropine eyedrops can reduce AL change in 1 year (MD -0.36, 95% CI -0.41 to − 0.30), with moderate inconsistency among studies (*I*^*2*^ = 46%) and moderate evidence quality (Additional file [1](#MOESM1){ref-type="media"}: Appendix 6).

Two adverse events, including blurred near vision and allergic/hypersensitivity reactions or discomfort, were separately reported by two index publications. Two RCTs (540 children) showed that 1% atropine solution may induce blurred near vision (OR 9.47, 95% CI 1.17 to 76.78; Table [6](#Tab6){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendices 5 and 6). One RCT and one cohort study (446 children) revealed an effect of 1% atropine for hypersensitivity reactions (OR 8.91, 95% CI 1.04 to 76.03), while no inconsistency exists between these two studies (*I*^*2*^ = 0%). One RCT (400 children) provided data on myopic progression and axial elongation for 2 years. Atropine appeared to reduce RE change (MD -0.92, 95% CI -1.08 to − 0.76) and favour AL change (MD -0.36, 95% CI -0.43 to − 0.29) compared to placebo (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendices 4 and 6).

### 0.025 To 0.05% atropine vs control {#Sec21}

Three cohort studies (224 children) examined this comparison. An effect on refraction change in 1 year was reported (MD -0.51, 95% CI -0.60 to − 0.41), favouring atropine, while low inconsistency exists among these studies (*I*^*2*^ = 9%; Table [2](#Tab2){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendices 4 and 6).

### 0.01% atropine vs control {#Sec22}

One cohort study (60 children) reported favourable effect of 0.01% atropine on RE change in 1 year (MD -0.50, 95% CI -0.76 to − 0.24, GRADE evidence quality: very low, Table [2](#Tab2){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendices 4 and 6).

### 2% Pirenzepine gel vs placebo {#Sec23}

Two RCTs (264 children) examined the effect of pirenzepine in myopic progression. Findings showed that pirenzepine has a favourable effect on AL change, reducing it by − 0.10 mm in 1 year (95% CI, − 0.18 to − 0.01; GRADE evidence: moderate; Table [4](#Tab4){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendix 6). Nonetheless, a number of reactions have been reported for this agent. Pirenzepine is more likely to induce abnormality of accommodation (OR 16.92, 95% CI 6.27 to 45.64) and subjectively reduce visual acuity (OR 3.89, 95% CI 0.93 to 16.27), while other adverse reactions had a smaller measure of effect (Additional file [1](#MOESM1){ref-type="media"}: Appendix 5). A full list of AE is provided in Table [6](#Tab6){ref-type="table"}.

### RGPCLs vs spectacles or SCLs {#Sec24}

Two RCTs (420 children) failed to identify any effect of RGPCLs on myopic progression (Tables [2](#Tab2){ref-type="table"} and [4](#Tab4){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendices 4 and 6). Although findings favour RGPCLs in reduction of refractive change, substantial inconsistency exists for both 1-year (*p* = 0.0008, *I*^*2*^ = 91%), and 2-year outcomes (*p* = 0.0005, *I*^*2*^ = 92%). Mean AL change did not differ between the two groups according to 1- and 2- year findings (Tables [3](#Tab3){ref-type="table"} and [5](#Tab5){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendices 4 and 6).

### Concentric ring bifocal SCLs vs SVSCLs {#Sec25}

Three RCTs (264 children) showed an effect of concentric ring bifocal SCLs on myopia control, with low quality of evidence (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendices 4 and 6). These trials reported a change of − 0.31D in 1 year, favouring concentric ring bifocal lenses (95% CI, − 0.60 to − 0.02). Due to high inconsistency (*p =* 0.0003, *I*^*2*^ = 88%), sensitivity analysis was performed. Exclusion of *Aller* et al. revealed a change of − 0.15D, favouring concentric ring bifocal lenses (95% CI, − 0.27 to − 0.03), with no existing inconsistency between studies (*p* = 0.35, *I*^*2*^ = 0%).The three trials (264 children) also compared mean AL change between concentric ring bifocal lenses and control in 1 year. Treatment with this type of lenses decreased AL change by − 0.12 mm (95% CI, − 0.19 to − 0.06). Two trials (261 children) reported contact lens-related discomfort or unwillingness to wear contact lenses (OR 0.95, 95% CI 0.49 to 1.81, Table [6](#Tab6){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendices 5 and 6).

### Peripheral add multifocal SCLs vs SCLs or SVLs {#Sec26}

Two RCTs (105 children) and three cohort studies (189 children) examined this comparison. Subgroup analysis of two RCTs showed no change in refraction in 1 year (MD -0.13D, 95% CI -0.28 to 0.02), but revealed an effect in AL change in 1 year (MD -0.11, 95% CI -0.17 to − 0.05), favouring peripheral add multifocal lenses. Subgroup analysis of cohort studies revealed a treatment effect of multifocal lenses in refraction and AL change in 1 year, (MD -0.27D, 95% CI -0.38 to − 0.17) and (MD − 0.08 mm, 95% CI -0.16 to − 0.01), respectively. The overall treatment effect (294 children) showed that peripheral add multifocal lenses can slow refractive change in 1 year (MD -0.23D, 95% CI -0.31 to − 0.14), with no existing inconsistency among studies (*I*^*2*^ = 0%) and very low evidence quality (Table [2](#Tab2){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendices 4 and 6). Two cohort studies (99 children) provided outcomes of the effect of peripheral add multifocal lenses in 2 years with very low evidence quality (Table [3](#Tab3){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendices 4 and 6). Findings revealed that multifocal lenses can slow myopic progression, by reducing RE change (MD -0.50D, 95% CI -0.65 to − 0.36) and by restricting axial elongation (MD − 0.13 mm, 95% CI -0.20 to − 0.06).

### OK vs SCLs or SVLs {#Sec27}

Three RCTs (115 children) and 8 cohort studies (548 children) investigated the use of orthokeratology for myopia control. Subgroup analysis of two RCTs (113 children) showed a change of − 0.19 mm in axial elongation in 1 year, favouring OK (95% CI, − 0.25 to − 0.13). Similarly, subgroup analysis of six cohort studies (411 children) revealed favourable effect of OK in AL change in 1 year, which was reduced by − 0.18 mm (95% CI, − 0.22 to − 0.15). The overall treatment effect (524 children) with moderate evidence quality showed that OK can reduce AL change in 1 year by − 0.19 mm compared to control (95% CI, − 0.21 to − 0.16), with no inconsistency among studies (*I*^*2*^ = 0%; Table [4](#Tab4){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Appendices 4 and 6). Three RCTs (108 children) investigated AL change in 2 years. Subgroup analysis of the clinical trials showed that mean AL change was − 0.27 mm, favouring OK (95% CI, − 0.36 to − 0.18). *Chan* et al. reported on each eye separately and due to unit of analysis issues, sensitivity analysis excluding *Chan* et al. revealed mean AL change of − 0.28 mm, favouring OK (95% CI, − 0.38 to − 0.19). Eight cohort studies (555 children) reported on the same outcome for 2 years of OK treatment. Subgroup analysis revealed that OK induced AL change of − 0.27 mm (95% CI, − 0.31 to − 0.22). Total effect of RCTs and cohort studies (663 children) revealed that OK restricts axial elongation (MD − 0.27 mm, 95% CI -0.31 to − 0.23), with no inconsistency among studies (*I*^*2*^ = 0%). Mild corneal erosion was reported by two cohort studies (151 children) as an adverse event (OR 4.56, 95% CI 0.49 to 42.25; Table [6](#Tab6){ref-type="table"}).

### PALs vs SVLs {#Sec28}

Six trials (1151 children) provided moderate quality evidence on the effect of PALs in progression of myopia. The overall pooled analysis of two RCTs (206 children) showed that children treated with PALs achieved greater reduction in RE change in 1 year, (Table [2](#Tab2){ref-type="table"}). Two RCTs (211 children) investigated the effect of PALs on AL change in 1 year, which was restricted by − 0.06 mm, favouring PALs (95% CI, − 0.12 to − 0.00; Table [4](#Tab4){ref-type="table"}). Two-year results on refraction change were reported by four RCTs (940 children). PALs appeared to reduce RE change by − 0.26D (95% CI, − 0.39 to − 0.12), with moderate inconsistency among studies (*I*^*2*^ = 59%). Three RCTs (791 children) estimated AL change in 2 years. PALs induced a change of − 0.10 mm (95% CI -0.20 to 0.00) but with considerable inconsistency among studies (*I*^*2*^ = 78%). Sensitivity analysis excluding *Leung* et al. demonstrated no difference in this case.

Discussion {#Sec29}
==========

This overview represents a comprehensive and thorough review of high level evidence from systematic reviews and meta-analyses on the efficacy and safety of optical and pharmaceutical modalities for restriction of myopic progression in children. Through this study, care was taken to identify and include all relevant methodologically robust primary studies and utilize them to perform an extensive meta-analysis, in order to fully depict current knowledge for retarding juvenile myopia. Owing to the reasonably limited number of published RCTs in this field so far, we incorporated high quality cohort studies in our analysis.

Existing high-level evidence suggests that atropine eyedrops appear to be more effective for myopia control compared to spectacles or CLs (Additional file [1](#MOESM1){ref-type="media"}: Table S9). Our findings are also in line with the consensus published by the World Society of Paediatric Ophthalmology and Strabismus (WSPOS), which reported that atropine is the most beneficial intervention for myopia progression control \[[@CR40]\]. In addition, modern orthokeratology also demonstrates efficacy in retarding myopia development compared to other types of lenses \[[@CR10], [@CR41]\], though its use is considerably limited by the associated high risk for microbial keratitis \[[@CR42], [@CR43]\]. Multifocal CLs designed with novel technology appear as an emerging treatment which has also proved to be effective, and has a low reported risk for infectious keratitis \[[@CR11]\]. Finally, there is increasing evidence that outdoor exposure in children has a protective effect on myopia development and should be readily encouraged \[[@CR12]\].

Despite the apparent beneficial effect of atropine, it has not been widely adopted for myopia treatment \[[@CR28], [@CR29]\]. Atropine eyedrops (1%) have been approved by U.S. Food and Drug Administration (FDA) for amblyopia treatment, but not for myopia control, and a diluted preparation (0.01%) does not exist in the market in most countries. Α drawback of atropine is the fact that myopic patients still need spectacles or contact lenses for good distant vision, while the combination of atropine with multifocal or bifocal spectacles has not shown any advantage \[[@CR44]\]. There exists a relatively small, but not scarce, subgroup of myopic individuals who do not respond to this treatment. Notably lacking is an evidence-based and widely accepted management plan that would define indications for treatment, timing of initiation and discontinuation, taking into account age, severity of myopia, rate of myopia progression, family history of myopia, race etc. \[[@CR28]\]. Wu et al. proposed a treatment strategy for myopia control with the use of 0.01% atropine solution. Authors advocated initial treatment with atropine for 2 years and in case of rapid progress, combination of atropine with time outdoors, stepwise increase in concentration or implementation of alternative therapy, such as orthokeratology. Decision on continuation of treatment after 2 years relied on the myopia progression rate. However, uncertainty still remains regarding poor responders, as well as treatment duration and whether a wash-out period is deemed necessary \[[@CR45]\].

When it comes to optimal atropine dose choice, findings from our meta-analysis are concordant with recent evidence from a network meta-analysis in 2016 \[[@CR34]\] and another meta-analysis in 2017 \[[@CR9]\] which showed no dose dependence and no difference in the efficacy of atropine across different doses in the range of 0.01--1%. Nonetheless, latest findings from Phase 1 of the LAMP study unveiled a concentration-dependent pattern of decelerating myopic progression among low dosages (0.01--0.05%) of atropine. These 1-year findings demonstrated that 0.01% atropine was effective in reducing refractive change, but not in restricting axial elongation \[[@CR46]\]. Concordant results after 1 year of follow-up had been previously reported by ATOM 2 study \[[@CR47]\]. LAMP proposed the use of 0.05% atropine as an optimal dose for obtaining clinically important outcomes, with a minimum risk for adverse reactions including photophobia, reduction in accommodative amplitude and pupillary dilation \[[@CR46], [@CR48]\]. Notwithstanding, five-year results from ATOM2 study supported binocular daily application of 0.01% atropine as the safest and most effective concentration for restricting myopia, as it appears that a plateau effect occurs following prolonged use of atropine with regard to clinically meaningful results \[[@CR47]\]. Furthermore, higher doses of atropine have been associated with increased risk for adverse events, such as photophobia, poor near visual acuity, allergy and rebound effect \[[@CR9], [@CR47]\]. An inverse dose-related rebound effect upon treatment discontinuation has also been described \[[@CR28]\]. Pirenzepine, which acts only to M1 anti-muscarinic receptors that are less concentrated in ciliary body and iris, is believed to have a lower impact on dilatation of the pupil or accommodation compared to atropine. Despite the encouraging findings shown by two RCTs, research on this agent has been abandoned, due to related costs and regulatory purposes \[[@CR49], [@CR50]\]. Further research in this area is warranted to investigate long-term efficacy of lower atropine concentrations, long-term adverse reactions, as well as the rebound phenomenon \[[@CR48]\].

Modern orthokeratology has been described as a major effective alternative to atropine for myopia treatment. Orthokeratology lenses are worn overnight and provide the advantage of clear vision during the day without the need for optical correction. Findings from a recent RCT showed that stopping OK use after 2 years of treatment results in greater axial growth compared to individuals who continued treatment, but similar to those who wore spectacles during this 2-year period. Interestingly, axial elongation was retarded after resuming the lenses for a 6-month period. However, more evidence on the effect of OK is needed \[[@CR51]\], especially with regards to its safety whereby major concerns have been raised \[[@CR10], [@CR32]\]. A recent systematic review reported on the infectious keratitis clinical profile following OK lens use. The study included 173 eyes of 166 patients with this complication and suggested that in spite of early treatment, most infections caused formation of corneal scars and nearly 10% of the cases required surgical treatment \[[@CR43]\]. Robust evidence on the overall incidence of keratitis was not available. Another systematic review on the safety of OK reported corneal staining as the most prominent side effect, along with lens binding and reduced tear film stability in long-term use. Orthokeratology side effects have resulted in this treatment presenting higher dropout rates compared to other myopia interventions. Patient training on proper fitting of the lenses and advice on timely attendance in case signs of ocular infection appear, is crucial \[[@CR33], [@CR39], [@CR42], [@CR43]\].

The use of modern multifocal soft CLs designed with novel technology has also been recently highlighted for myopia management. Initially, a number of clinical studies were conducted on bifocal lenses for myopia control. These lenses incorporate two parts for distance and near vision, which are clearly demarcated and, therefore, produce a prismatic effect \[[@CR52]\]. In accord, modern types of concentric ring bifocal soft CLs consist of a center-distance zone enclosed by multiple rings of power with near addition, while peripheral add multifocal soft CLs are made of center-distance zone surrounded by progressively increasing power which gradually becomes positive in the periphery. The design of multifocal lenses is based on the imposition of myopic defocus at all distances, which aims to employ emmetropisation process so as to retard progression of myopia \[[@CR53], [@CR54]\]. Multifocal CLs demonstrate lower risk of ocular infections compared to overnight lenses. Multifocal spectacles have also been reported to produce similar outcomes \[[@CR11]\]. Findings of the RCT investigating multiple segment (MS) spectacle lenses (NCT02206217) will provide more clinical data on this intervention. Future designs of multifocal lenses should aim to provide higher retinal image quality \[[@CR11]\].

Increased outdoor exposure is yet another myopia-controlling intervention for which the mechanism of action has not been clarified. Index publications assessing outdoor exposure are not statistically analysed in this overview, due to serious limitations of the studies assessing this intervention: a) outcome measures and study design vary largely between these studies and additionally outcomes are distinct from ours, b) a number of them have broad age range of participants involving adults, c) observational studies present several types of biases such as recall bias and loss to follow-up, finally d) synthesizing evidence from RCTs and observational studies, mainly cross-sectional ones, would probably provide imprecise estimates. Lastly, current evidence on the effect of outdoor exposure reflects controversy. A systematic review and meta-analysis analysing up-to-date evidence showed that outdoor exposure appears to provide protection from myopia onset in nonmyopes, but does not result in restriction of myopia progression in already myopic individuals \[[@CR12]\]. In contrast, a recent RCT reports a beneficial effect of outdoor exposure in both nonmyopic and myopic individuals \[[@CR55]\]. Additional evidence on this area is expected from clinical trials underway (NCT02980445, NCT03552016).

Optical undercorrection has been another debatable issue, as studies have produced contradictory results over the years. Our meta-analysis showed that full correction reduces progression of myopia compared to undercorrection over a 2-year period of treatment \[[@CR56], [@CR57]\]. A retrospective cohort study by Vasudevan et al. also supports this finding \[[@CR58]\]. Nonetheless, a recent cohort study on 121 Chinese children proposed that abstinence from correction is effective in slowing myopic progression and axial elongation compared to full correction \[[@CR59]\], which is in line with former findings from animal studies \[[@CR60], [@CR61]\]. Undercorrection on animal models imposes myopic defocus which was considered to slow myopic progression. This intervention proved effective in animals, possibly because it was implemented at a very early stage of development, in contrast to the majority of human studies \[[@CR58]\].

To our knowledge, this is the first overview of systematic reviews and meta-analyses on interventions for myopia control. Through this study, we identified and synthesized all available high level evidence, estimated the actual overlap of index publications that composed eligible reviews, and reported on efficacy and safety of myopia interventions. Certain limitations stand out in this overview. A number of treatments, such as atropine and OK, were represented by a larger number of reviews compared to other therapies, including bifocal or multifocal lenses. In one large SR \[[@CR5]\], dual co-authorship was identified, as two of the authors were principal investigators in two included trials and both of them were involved in quality assessment of the included index publications. A protocol was not available for the majority of eligible reviews, and one protocol amendment was reported \[[@CR5]\]. A large proportion of the eligible index publications contained in the systematic reviews were at high risk of bias for selective outcome reporting. Publication bias was suspected in eleven reviews, due to language restrictions and exclusion of unpublished material or conference abstracts. Included index publications were largely unable to achieve appropriate blinding and allocation concealment, mainly due to the nature of the investigated interventions (eyedrops, spectacles, contact lenses). Follow-up periods varied significantly among the trials, and losses to follow-up were also noted, mainly depending on the type of treatment and related adverse events. The majority of index publications were conducted in Asian ethnicities, which could compromise the external validity of their findings. Due to small sample sizes analysed, treatment effects are likely to be overestimated. Index publications either reported on one affected eye, or each eye separately, or provided the measure of effect as the average of both eyes \[[@CR62]\]. Finally, only 9 index publications reported on adverse events.

Conclusions {#Sec30}
===========

Our data suggest that atropine followed by orthokeratology and novel multifocal soft contact lenses demonstrate efficacy in controlling myopic progression. Future research should be geared towards effective interventions and their potential combinations. More evidence on low-dose atropine is needed and several parameters remain to be defined, such as the appropriate onset and duration of treatment, as well as the period needed for tapering off the medication without causing a rebound effect. ATOM3 study (NCT03140358) is underway and is expected to provide some answers to outstanding issues. It remains unclear if atropine or orthokeratology could lead to a permanent long-term effect on myopia control. Possible rebound effect upon treatment cessation should also be assessed for OK and multifocal lenses. In addition, more research in non-Asian ethnicities is needed. Methodologically rigorous trials with long-term follow-up and large sample sizes constitute the optimal study design for further investigating myopia interventions. Finally, systematic collection of evidence on safety issues is essential, as these treatments gradually enter routine practice all over the world.
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